NeuBase Therapeutics Inc
F:O7PA
NeuBase Therapeutics Inc
Total Liabilities & Equity
NeuBase Therapeutics Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NeuBase Therapeutics Inc
F:O7PA
|
Total Liabilities & Equity
$18.6m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
10%
|
CAGR 10-Years
12%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities & Equity
$133.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities & Equity
$59B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities & Equity
$90.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities & Equity
$25.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities & Equity
$40.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
NeuBase Therapeutics Inc
Glance View
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
See Also
What is NeuBase Therapeutics Inc's Total Liabilities & Equity?
Total Liabilities & Equity
18.6m
USD
Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's Total Liabilities & Equity amounts to 18.6m USD.
What is NeuBase Therapeutics Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
12%
Over the last year, the Total Liabilities & Equity growth was -43%. The average annual Total Liabilities & Equity growth rates for NeuBase Therapeutics Inc have been -19% over the past three years , 10% over the past five years , and 12% over the past ten years .
